As far as we know, some phenotypic characteristics may relate to clinical outcome in AML patients, i.e, CD34 negativity related with NPM1 mutation, CD56 expression in AML with (8;21), or CD2, CD36, CD11b or CD56 positivity in other types of AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.